Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQW051 PD and Safety in Schizophrenia
NCT00825539Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AQW051 in schizophrenia, sponsored by Novartis. Started Jan 2009; status: completed.
02
Drugs
AQW051
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00825539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00825539.